SCHEMBL4155484

SCHEMBL4155484

NC(=O)c1ccccc1Oc1ccc(Cl)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.74
MAPT P10636 3/20 0.60
RAB9A P51151 2/20 0.59
BRD4 O60885 1/20 0.58
HTT P42858 2/20 0.54
ALDH1A1 P00352 1/20 0.54
GAA P10253 1/20 0.54
HPGD P15428 1/20 0.54
ATM Q13315 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NPC1 O15118 1/20 0.51
P2RX3 P56373 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PARP10 Q53GL7 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
PNLIP P16233 3/20 0.48
NR1I2 O75469 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28876495 0.85 CTNNB1 (1.00) CTNNB1MAPTRAB9ABRD4HTT
SCHEMBL27680126 0.85 CTNNB1 (1.00) CTNNB1MAPTRAB9ABRD4HTT
SCHEMBL5724 0.85 CTNNB1 (1.00) CTNNB1MAPTRAB9ABRD4HTT
SCHEMBL4142669 0.85 CTNNB1 (0.67) CTNNB1MAPTRAB9ABRD4HTT
SCHEMBL30775031 0.85 CTNNB1 (0.67) CTNNB1MAPTRAB9ABRD4HTT
SCHEMBL1892492 0.84 CTNNB1 (0.77) CTNNB1MAPTALDH1A1HPGDMEN1
SCHEMBL2778881 0.84 MAPT (0.61) CTNNB1MAPTHTTALDH1A1GAA
SCHEMBL29842430 0.84 MAPT (0.61) CTNNB1MAPTHTTALDH1A1GAA
SCHEMBL27800575 0.84 CTNNB1 (0.77) CTNNB1MAPTALDH1A1L3MBTL1MEN1
Hydrochloric Acid SCHEMBL50731 0.84 CTNNB1 (0.96) CTNNB1MAPTRAB9ABRD4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960347-B1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS STERIX LTD (GB) 2012-06-20 EP disclosed
US-20090023710-A1 Compound OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2009-01-22 US disclosed
EP-1960347-A2 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS Sterix Limited (GB) 2008-08-27 EP disclosed
WO-2007003934-A2 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS STERIX LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023710-A1 Compound NR1H3, NR1H2, NR1H4 CTNNB1 2627/4885MAPT 4851/4885RAB9A 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.